Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial

Multiple myeloma (MM) is a heterogeneous hematologic malignancy associated with several risk factors including genetic aberrations which impact disease response and survival. Thorough risk classification is essential to select the best clinical strategy to optimize outcomes. The SKY92 molecular sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Biran, Noa, Dhakal, Binod, Lentzsch, Suzanne, Siegel, David, Usmani, Saad Z., Rossi, Adriana, Rosenbaum, Cara, Bhutani, Divaya, Vesole, David H., Rodriguez, Cesar, Nooka, Ajay K., van Rhee, Frits, Stork‐Sloots, Lisette, de Snoo, Femke, Bhattacharyya, Pritish K., Dash, Durga Prasad, Zümrütçü, Sena, van Vliet, Martin H., Hari, Parameswaran, Niesvizky, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175784/
https://www.ncbi.nlm.nih.gov/pubmed/35844693
http://dx.doi.org/10.1002/jha2.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175784/
https://www.ncbi.nlm.nih.gov/pubmed/35844693
http://dx.doi.org/10.1002/jha2.209

Ejemplares similares